Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07248144 plus fulvestrant versus investigator's choice treatment in HR-positive, HER2-negative advanced or metastatic breast cancer
NL-OMON59734Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of prifetrastat and fulvestrant in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Dec 2025; status: recruiting.
02
Drugs
prifetrastatfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59734.